2.4.0.82418401 - Disclosure - Collaboration Agreements (Details)truefalsefalse1false USDfalsefalse$D2013Q2QTDhttp://www.sec.gov/CIK0001113481duration2013-04-01T00:00:002013-06-30T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$D2012Q2http://www.sec.gov/CIK0001113481duration2012-04-01T00:00:002012-06-30T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D2013Q2YTDhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$D2012Q2YTDhttp://www.sec.gov/CIK0001113481duration2012-01-01T00:00:002012-06-30T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]2false 4mdco_CoPomotionIncomemdco_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse40680004068000USD$falsetruefalse2truefalsefalse25000002500000USD$falsetruefalse3truefalsefalse78180007818000USD$falsetruefalse4truefalsefalse25000002500000USD$falsetruefalsexbrli:monetaryItemTypemonetaryCo-Pomotion IncomeNo definition available.false2Co-promotion income3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$D2013Q2YTD_us-gaap_TypeOfArrangementAxis_mdco_AstraZenecaMemberhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseAstraZeneca [Member]us-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldimdco_AstraZenecaMemberus-gaap_TypeOfArrangementAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0AstraZeneca [Member]4true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]5false 4mdco_CollaborativeArrangementTermforCoPromotionmdco_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse004 yearsfalsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaCollaborative Arrangement, Term for Co-PromotionNo definition available.false0Term for co-promotion6false 4mdco_CoPomotionIncomemdco_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1780000017800000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCo-Pomotion IncomeNo definition available.false2Co-promotion income7false 4mdco_CollaborativeArrangementTerminationFeemdco_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse50000005000000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCollaborative Arrangement, Termination FeeNo definition available.false2Termination fee8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse6false USDtruefalse$D2013Q2YTD_us-gaap_TypeOfArrangementAxis_mdco_AlnylamPharmaceuticalsInc.Memberhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseAlnylam Pharmaceuticals, Inc. [Member]us-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldimdco_AlnylamPharmaceuticalsInc.Memberus-gaap_TypeOfArrangementAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Alnylam Pharmaceuticals, Inc. [Member]9true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]10false 4mdco_CollaborativeArrangementCashPaymentmdco_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2500000025000000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse2500000025000000USD$falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCollaborative Arrangement, Cash PaymentNo definition available.false2Initial payment11false 4mdco_CollaborativeArrangementPaymentforMilestoneMet1mdco_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse180000000180000000USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCollaborative Arrangement, Payment for Milestone Met1No definition available.false2Maximum payment for success-based development and commercialization milestonesfalseCollaboration Agreements (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.themedicinescompany.com/role/CollaborationAgreementsDetails411